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bstract
Gastrointestinal microbes play important roles in the health and disease of the host. There are many documented evidences which demonstrated
hat disturbance of intestinal microbiota is linked to the risk of developing infectious, inflammatory and allergic diseases. Human intestine is home
or a complex consortium of 1013–1014 microbial cells. Interactions between the intestinal microbes, pathogens and the host lead to exclusion
f toxins (mycotoxins) and pathogens (colonization resistance), interference in disease progression as demonstrated in the prevention of oral
nfection, dental caries, diarrhoeas (Antibiotic Associated Diarrhoea, Travellers’ Diarrhoea and Rotavirus Diarrhoea), postoperative infection,
espiratory infection and certain cancers. The group of beneficial intestinal microbes termed probiotics alter intestinal epithelial cell tight junction
nd immunological functions. Lately, laboratory and clinical studies demonstrated gut-brain axis communication and intestinal microbial (both
athogens and probiotics) modulation of host psycho-neuroimmunological functions, in relation to depression, anxiety and memory dysfunction.
hese open up many possibilities of probiotics supplementation for moderating intestinal microbiota as an approach in disease prevention and
reatment.
y Els
2
h
n
b 2014 Beijing Academy of Food Sciences. Production and hosting b
.  Introduction
The intestinal tract of adult carries 1–2 kg of microbes. It
s a common knowledge that pathogenic microbes could cause
nfectious diseases such as diarrheal, while others are associated
ith inflammatory and allergic diseases [1–3].
On the other hand, the majority of the gut microbes do pro-
ect us from pathogens via colonization resistance, modulation
f immunity, and benefit us through digestion of foods and
roduction of vitamins. Thus it is logical to assume that the
upplementation of selected microbes could impart beneficial
ffect to us and they are termed probiotics. The FAO/WHO have
efined probiotics living microorganisms which when adminis-
ered in adequate amounts confer a health benefit on the host
4].∗ Corresponding author at: Tel.: +65 65163284.
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.  Factors  determining  the  microbial  colonization  of
uman  intestinal  tract
We are born with a sterile gastrointestinal tract (GI), its colo-
ization begin at birth. The GI microbiota profile is determined
y a number of factors:
(i) Exposure  after  birth  and  during  infancy. The window for
colonization of GI tract is within the first two years after
birth. Once established, it is difficult for a new comer
to replace the commensal microbes, such is termed col-
onization resistant [5], unless the long term diet habit and
physiology changed with life style and age. As expected
the GI microbiota profile of infant born by natural birth
and those by caesarean birth are different [6,7]. Caesarean
birth infants and infants who are not frequently exposed to
microbes in the environment are prone to develop allergic
diseases, such as atopic eczema and asthma [8,9].
(ii) Survival  in  GI  environments  and  adhesion  on  GI  surface.
The microbes that reach our GI tract need to survive through
the passage and adhere on GI mucosal surface to colonize,
and to establish interaction with the host. The stomach and
large intestine are acidic while the small intestine is alka-
line. The incoming microbes also need to tolerate the action
of digestive enzymes, such as the proteases, amylases and
lipases. The adhesion–receptor interaction on the surface of
the GI tract often involves specific carbohydrate moieties
on the surface of the microbes and the GI surface [10], thus
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the carbohydrate diet may interfere with the colonization
of microbial types.
iii) Colonization  of  GI  surface. The ability of the incoming
microbes to colonize and reproduce in specific segment of
our GI tract is determined by the microenvironment, which
in turn is largely determined by the physiology stage of the
host and the dietary habit [11,12].
.  Scientiﬁc  and  clinically  demonstrated  probiotic
ffects
The following summarizes scientific and clinically demon-
trated beneficial effects of selected probiotics.
(i) Diarrhoeas. It is reasonable to assume that a newly arriv-
ing diarrheic microbes would find it difficult to establish
in a GI tract that is clouded with commensal microbes.
It is therefore not surprising that one of the earlier clin-
ical demonstration of probiotic effect is the prophylactic
prevention of antibiotic-associated diarrhoeas with lacto-
bacilli preparation [13]. In the placebo group of elderly
patients (median age 65) taking ampicillin, 14% suffered
from diarrhoea, while none of the subject (median age 64)
taking a lactobacillus preparation Lacttinex went down
with diarrhoea. The anti-diarrhoeic mechanism of probio-
tics appear to be both competition for adhesion on mucosal
surface [14] and their immunogenicity for recovery [15].
(ii) Allergic  diseases. The immunomodulating effect of pro-
biotics is best demonstrated in their prevention of atopic
eczema in infants [16–18]. A dosage of 2 ×  1010 CFU/day
was delivered for 2–4 weeks to the mothers before
expected delivery, and to the infants for 6 months. Such
preventive effect was evidence from birth to at least 7
years old. To date, more than 10 clinical trials using var-
ious probiotics had been conducted to demonstrate the
anti-allergic effect of probiotics. Most of them showed
positive effect but three trials using same probiotics and
protocol showed negative effect. This suggested that host
factors could be involved in the disease preventing pro-
biotic effects.
(iii) Chronic  idiopathic  inﬂammatory  bowel  diseases. Ther-
apeutic approaches that correct the aberrancies in
microbiota and eliminate the inflammation inducing
bacteria and adjuvants for the treatment of IBD, in con-
junction with anti-inflammatory and immunosuppressant
agents, showed best results in pouchitis [19] and to a lesser
extent ulcerative colitis [20].
It should be mentioned that probiotic effect in reliev-
ing IBS symptoms is strain specific. Lactobacillus  casei
Shirota strain showed positive (89% probiotic vs 56%
placebo) on constipation and stool consistency but no
change in degree of flatulence and bloating sensation
in chronic idiopathic constipation patients (either sex,
age 18–70) in 4 weeks [21]. L.  plantarum  299v reduced
flatulence significantly (6.5–3.1 per day in test group
vs 7.4–5.6 per day in placebo), however no significant
difference between test and placebo in abdominal pain andn Wellness 3 (2014) 47–50
defecation function was observed in 4 weeks [22]. On the
other hand, a study on the L.  rhamnosus, even at a large
dosage (1 ×  1010 CFU/d) showed no significant reduction
in flatulence, abdominal pain and defecation function in
test group compared to the placebo [23].
(iv) Mucosal  immunity. The continued consumption of pro-
biotics Lactobacillus  gasseri  PA16/8, Biﬁdobacterium
longum  SP07/03 and B.  biﬁdum  MF20/5 for two Winters
and Springs did not show difference in incidence of com-
mon cold among non-vaccinated healthy adults (18–67
years) [24,25]. The duration of episode was nevertheless
shortened by almost 2 d (Placebo 8.9 ±  1.0 vs probiotic
7.0 ±  0.5 d), with accompanied increase in cytotoxic T
cells and T suppressor cells.
Orally consumed probiotics ascend to the vaginal tract
after they are excreted from the rectum; vaginal adminis-
tration allows for direct replacement of the probiotics for
unhealthy vaginal microbiota and consequently results in
maintenance of a low pH and production of antimicro-
bial substances like acids and hydrogen peroxide. Data
from 127 patients in two studies showed a statistically
significant decrease in recurrence of bacterial vaginosis
in patients given Lactobacillus  [26,27].
In a different study, oral intake of probiotic VSL#3
during the last trimester of pregnancy countered the
decrease of Biﬁdobacterium  and the increase of Atopo-
bium, that occurred in control women during late
pregnancy. The modulation of the vaginal microbiota was
associated with the maintenance of anti-inflammatory
cytokines IL-4 and IL-10, and the decrease of the pro-
inflammatory chemokine Eotaxin, suggesting a potential
anti-inflammatory effect on the vaginal immunity, with
potential implications in preventing preterm birth [28].
(v) Cancers. Nasopharyngeal carcinoma, rectal cancer, breast
cancer and bladder cancer have been associated with diets
high in nitrate, fat and protein [29–31]. The presence of
certain GI bacteria such as Escherichia  coli, Clostrid-
ium sp. and Peptostraptococcus  sp. could transform
dietary components into carcinogens [32–34]. Compet-
itive replacement of carcinogen-producing bacteria by
L. casei  Shirota (oral 1 ×  1010 CFU three times daily)
prolonged recurrence-free period of superficial bladder
cancer after transurethral resection [35,36]. Habitual con-
sumption of the same probiotic bacterium (L.  casei
Shirota) by patients with multiple colorectal adenomas
or early cancers (age 40–65) showed adjusted odds ratio
of developing at least one tumour of 0.76 after 2 years and
0.85 after 4 years. The relative risk of developing adeno-
mas with moderate or severe atypia decreased from 0.80
after 2 years to 0.65 after 4 years, while measurement of
short-chain fatty acids in faeces showed an increase in
butyric acid content during lactobacilli treatment [37].
(vi) Metabolic  disorders. High-fat diet may change intesti-
nal microbiota profile result in reduced epithelia barrier
function, increased endotoximia, chronic low-grade sys-
temic inflammation and ultimately metabolic disorders
[38,39]. Supplementation of probiotics could be a route
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in reverting the microbiome imbalance and metabolic dis-
order [40,41].
(vii) Mental  state. Forced Swimming Test (FST) is a model
for predicting the extent of depression in rodents; the
increased immobility in this test is considered a reflec-
tion on the state of behavioural despair. It was observed
that young rodents separated from mothers showed double
the count of immobility as compared to the control in the
FST. Depressed rodents treated with the anti-depressant
drug citalopram reduced the immobility count, so did the
supplementation of the probiotic Biﬁdobacterium  infan-
tis to the level of the control [42]. In a rodent model
chronic fatigue (28 d exposure to FST), administration
of L.  acidophilus  (vs placebo) reduced immobility and
post-swim fatigue, in tandem with reduction in brain mea-
surements of oxidative stress inflammatory cytokine (TNF
alpha) [43]. Such observations in the animal studies are in
accordance with human intervention study, where L.  casei
fermented beverage was found to improve mood scores
of healthy adults with mild depression symptoms, and
improvement in anxiety by Beck Anxiety Inventory after
eight weeks of consumption of the fermented beverage
[44,45].
viii) Memory. It was an unexpected observation that the mem-
ory of germ-free mice was impaired as compared to
normal mice as shown in Novel Object Test [46]. Memory
lost could be prevented by dietary probiotic supple-
mentation, and was due to restoration of hypocampal
Brain-derived Neurotropic Factor (BDNF) and expression
of c-Fos in the hippocampus. There appears to be multi-
ple lines of communication between the gut and our brain
[47,48]: (1) gut microbes lower oxidative stress and sys-
temic inflammatory cytokines; (2) gut microbes influence
neurotransmitter precursor levels via amino acids and neu-
ronal membrane structure via fatty acids (the vagus nerve
conduit); (3) gut microbes attenuate intestinal permeabil-
ity through attenuation of hypothalamic-pituitary-adrenal
(HPA) axis response and reduce central neuroin-
flammation; (4) gut microbes lower uraemic toxin
burden.
.  Conclusion
Human gut home for a complex consortium of 1013 to 1014
acterial cells, outnumber the body cells of the host by a factor
f 10. Gut microbiota and its microbiome should be considered a
uidized genetic and metabolic component of us. Thus harness-
ng functionality of probiotics as ingredient of functional foods
s a desirable approach in the promotion of health and disease
revention.eferences
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